Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | PLAT | P00750 | 1/20 | 0.41 |
| ▸ | NCF1 | P14598 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GMNN | O75496 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7403628 | 1.00 | LMNA (0.41) | LMNAPLGPLATNCF1EPHX2 | |
| SCHEMBL7397429 | 1.00 | LMNA (0.41) | LMNAPLGPLATNCF1EPHX2 | |
| SCHEMBL7402914 | 1.00 | LMNA (0.41) | LMNAPLGPLATNCF1EPHX2 | |
| SCHEMBL7404625 | 1.00 | LMNA (0.41) | LMNAPLGPLATNCF1EPHX2 | |
| SCHEMBL6476697 | 1.00 | LMNA (0.41) | LMNAPLGPLATNCF1EPHX2 | |
| SCHEMBL7683856 | 0.82 | TP53 (0.31) | LMNATP53KDM4EGMNNMAPT | |
| SCHEMBL10216772 | 0.80 | NCF1 (0.42) | LMNAPLGPLATNCF1 | |
| SCHEMBL8275064 | 0.80 | NCF1 (0.42) | LMNAPLGPLATNCF1 | |
| SCHEMBL70093 | 0.80 | NCF1 (0.42) | LMNAPLGPLATNCF1 | |
| SCHEMBL760536 | 0.80 | APLNR (0.35) | CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6894041-B2 | Oxazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC (US) | 2005-05-17 | — | — | US | disclosed |
| US-6869945-B2 | Pyrrolyl-and imidazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC (US) | 2005-03-22 | — | — | US | disclosed |
| EP-1355907-A1 | THIAZOLYL-, OXAZOLYL-, PYRROLYL-, AND IMIDAZOLYL-ACID AMIDE DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | Pfizer Products Inc. (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20030186974-A1 | Pyrrolyl- and imidazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes | MARFAT ANTHONY (US) | 2003-10-02 | — | — | US | disclosed |
| US-20030130254-A1 | Oxazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes | MARFAT ANTHONY (US) | 2003-07-10 | — | — | US | disclosed |
| US-6559168-B2 | 3',5'-cyclic nucleotide phosphodiesterases (PDEs); disease related to eosinophils, such as asthma, chronic bronchitis, and chronic obstructuive pulmonary disease | PFIZER INC | 2003-05-06 | — | — | US | disclosed |
| WO-2002060898-A1 | THIAZOLYL-, OXAZOLYL-, PYRROLYL-, AND IMIDAZOLYL-ACID AMIDE DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER PRODUCTS INC. (US) | 2002-08-08 | — | — | WO | disclosed |
| US-6380218-B1 | FOR THERAPY OF RESPIRATORY, ALLERGIC, AND INFLAMMATORY DISORDERS COMPRISING ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ACUTE RESPIRATORY DISEASE SYNDROME, PULMONARY HYPERSENSITIVITY, AND ALLERGIC RHINITIS IN A MAMMAL | PFIZER INC | 2002-04-30 | — | — | US | disclosed |
| EP-0971894-A1 | NICOTINAMIDE DERIVATIVES | Pfizer Products Inc. (US) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998045268-A1 | NICOTINAMIDE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130254-A1 | Oxazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes | CBR1, NOX1, NOX3 | LMNA 2595/4885PLG 2663/4885PLAT 2320/4885 |
| US-20030186974-A1 | Pyrrolyl- and imidazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes | CBR1, PDE4A, PDE3B | LMNA 2319/4885PLG 2062/4885PLAT 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.